Update on heparin-induced thrombocytopenia and cardiovascular interventions

Seminars in Hematology

Volumn 42, Issue SUPPL. 3, 2005, Pages

  Spiess, Bruce D ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; HIRULOG; LEPIRUDIN;

BLEEDING; CARDIOVASCULAR SURGERY; CAUSE OF DEATH; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE SEVERITY; EVALUATION; GRAFT OCCLUSION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNITY; LIMB AMPUTATION; LIMB ISCHEMIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ANTICOAGULANTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CARDIAC SURGICAL PROCEDURES; HEPARIN; HIRUDINS; HUMANS; MULTICENTER STUDIES; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THORACIC SURGERY; THROMBOCYTOPENIA;

EID: 23644452498     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.05.014     Document Type: Conference Paper

References (41)

1. T.E. Warkentin, A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann Thorac Surg 76 2003 2121 2131
2. B. Lo, R. Fijnheer, D. Castigliego Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass Anesth Analg 99 2004 634 640
3. N. Li, R. Astudillo, T. Ivert Biphasic pro-thrombotic and inflammatory responses after coronary artery bypass surgery J Thromb Haemost 1 2003 470 476
4. J. Larmann Inflammatory response to cardiac surgery Cardiopulmonary bypass versus non-cardiopulmonary bypass surgery Best Pract Res Clin Anaesthesiol 18 2004 425 438
5. B.D. Spiess Unfractionated heparin for cardiopulmonary bypass An unnatural act? J Cardiothorac Vasc Anesth 14 2000 239 242
6. J. Hirsh, R. Raschke Heparin and low-molecular-weight heparin The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 suppl 2004 188S 203S
7. E. Young, M. Prins, M.N. Levine Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 1992 639 643
8. Z. Xiao, P. Theroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256
9. J.I. Weitz, B. Leslie, M. Hudoba Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin independent inhibitors Circulation 97 1998 544 552
10. M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker Quantification of heparin-induced TFPI release A maximum release at low heparin dose Br J Clin Pharmacol 54 2002 627 634
11. M.S. Avidan, J.H. Levy, J. Scholz A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass Anesthesiology 102 2005 276 284
12. K.W. Park Protamine and protamine reactions Int Anesthesiol Clin 42 2004 135 145
13. S.E. Kimmel, M. Sekeres, J.A. Berlin Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass Anesth Analg 94 2002 1402 1408
14. J. Amiral, D. Meyer Heparin-dependent antigens in heparin-induced thrombocytopenia T.E. Warkentin A. Greinacher Heparin-Induced Thrombocytopenia ed 3 2004 Marcel Dekker New York, NY 165 177
15. T.E. Warkentin Clinical picture of HIT T.E. Warkentin A. Greinacher Heparin-Induced Thrombocytopenia ed 3 2004 Marcel Dekker New York, NY 53 106
16. D.H. Lee, T.E. Warkentin Frequency of heparin-induced thrombocytopenia T.E. Warkentin A. Greinacher Heparin-Induced Thrombocytopenia ed 3 2004 Marcel Dekker New York, NY 107 148
17. G.P. Visentin, M. Malik, K.A. Cyganiak Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes J Lab Clin Med 128 1996 376 383
18. M. Trossaert, A. Gaillard, P.L. Commin High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery Br J Haematol 101 1998 653 655
19. C. Pouplard, M.A. May, S. Iochmann Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin Clinical implications for heparin-induced thrombocytopenia Circulation 99 1999 2530 2536
20. T.E. Warkentin Heparin-induced thrombocytopenia A clinicopathologic syndrome Thromb Haemost 82 1999 439 447
21. J.L. Francis, G.J. Palmer 3rd, R. Moroose Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery Ann Thorac Surg 75 2003 17 22
22. C. Pouplard, M.A. May, S. Regina Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies Blood 100 2002 16a 17a abstr
23. T.E. Warkentin, J.A. Sheppard, P. Horsewood Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood 96 2000 1703 1708
24. R.T. Williams, L.V. Damaraju, M.A. Mascelli Anti-platelet factor 4/heparin antibodies An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes Circulation 107 2003 2307 2312
25. M.L. Simoons GUSTO IV-ACS Investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation The GUSTO IV-ACS randomised trial Lancet 357 2001 1915 1924
26. A.V. Mattioli, L. Bonetti, S. Sternieri Heparin-induced thrombocytopenia in patients treated with unfractionated heparin Prevalence of thrombosis in a 1 year follow-up Ital Heart J 1 2000 39 42
27. T.F. Slaughter, E. Bennett-Guerrero, Z. Su Anti-heparin-PF antibodies detected prior to cardiac surgery identify patients at high risk for adverse perioperative outcomes Anesth Analg 93 2002 SCA28 abstr
28. T.E. Warkentin, A. Greinacher Heparin-induced thrombocytopenia: Recognition, treatment and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 suppl 2004 311S 337S
29. K.W. Mahaffey, B.E. Lewis, N.M. Wildermann The Anticoagulant Therapy with Bivalirudin to Assist in the performance of percutaneous coronary intervention in patients with heparin-induced Thrombocytopenia: (ATBAT) study: Main results J Invas Cardiol 15 2003 611 616
30. K.R. Campbell, K.W. Mahaffey, B.E. Lewis Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention J Invas Cardiol 12 suppl F 2000 1 11
31. A. Greinacher The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia Semin Thromb Hemost 30 2004 315 327
32. B. Poetzsch, K. Madlener Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia T.E. Warkentin A. Greinacher Heparin-Induced Thrombocytopenia ed 3 2004 Marcel Dekker New York, NY 531 551
33. M.A. Cannon, J. Butterworth, R.D. Riley Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery Ann Thorac Surg 77 2004 711 713
34. J.I. Weitz, E.R. Bates Direct thrombin inhibitors in cardiac disease Cardiovasc Toxicol 3 2003 13 25
35. R. Robson, H. White, P. Aylward Bivalirudin pharmacokinetics and pharmacodynamics Effect of renal function, dose, and gender Clin Pharmacol Ther 71 2002 433 439
36. J.A. Bittl, B.R. Chaitman, F. Feit Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina Final report reanalysis of the Bivalirudin Angioplasty Study Am Heart J 142 2001 952 959
37. A.M. Lincoff, J.A. Bittl, R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial JAMA 289 2003 853 863
38. A.M. Lincoff, N.S. Kleiman, D.J. Kereiakes Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization REPLACE-2 randomized trial JAMA 292 2004 696 703
39. D.P. Chew, A.M. Lincoff, H. Gurm Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial) Am J Cardiol 95 2005 581 585
40. A.F. Merry, P.J. Raudkivi, N.G. Middleton Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Ann Thorac Surg 77 2004 925 931
41. A. Koster, B. Spiess, D.P. Chew Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting Am J Cardiol 93 2004 356 359